CD38 and Miyoshi myopathy: These include panobinostat17 (a pan-histone deacetylase inhibitor), ixazomib (an oral proteasome inhibitor), elotuzumab (a monoclonal antibody targeting SLAMF7) and daratumumab (a monoclonal antibody targeting CD38) and have been approved in the United States for the treatment of MM, substantially expanding the number of treatment regimens available for patients.